background
banner

CAMLAN 30 mg

Active Substance: Lansoprazole.

33
UAD , based on 7541 reviews.
View Drug details
Overview

Welcome to Dwaey, specifically on CAMLAN 30 mg Delayed Release hard gelatin capsule page.
This medicine contains an important and useful components, as it consists of Lansoprazole.
CAMLAN 30 mg is available in the market in concentration 30 mg/Capsule and in the form of Delayed Release hard gelatin capsule.

ANNORA PHARMA FZ-LLC is the producer of CAMLAN 30 mg and it is imported from UAE, The most popular alternatives of CAMLAN 30 mg are listed downward .

Mode Of Action & Indication

Lansoprazole is a substituted benzimidazole, and is also known as PPI due to its property to block the final step of acid secretion by inhibiting H+/K+ ATPase enzyme system in gastric parietal cell. Both basal and stimulated acid are inhibited.

Indication
  • Peptic ulcer
  • H.pylori infection
  • Gastro-oesophageal reflux disease
  • Hypersecretory conditions
  • Acid-related dyspepsia
  • NSAID-induced ulcers
  • Erosive oesophagitis
Precaution

Hepatic impairment. Gastric malignancy should be ruled out. Pregnancy and lactation. Lactation: Not known whether distributed into breast milk; do not nurse

Side Effects
  • 1-10% Headache (3-7%)
  • Diarrhea (1-5%)
  • Constipation (1-5%)
  • Nausea (1-3%)
  • Abdominal pain (1-3%) <1% Anxiety
  • Angina
  • Palpitations
  • Syncope
  • Edema
  • Anorexia
  • Dry mouth
  • Tenesmus
  • Flatulence
  • Melena
  • Myalgia
  • Tinnitus
  • Allergic reaction
Alternatives Price List
  • ZEROPEP 30mgUAD 37
  • ZEROPEP 30mgUAD 74
  • ZEROPEP 30mgUAD 224
  • ZEROPEP 15mgUAD 16
  • ZEROPEP 15mgUAD 33
Contra indication

Hypersensitivity.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate. Potentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.

Releated Products

banner

Report Price Error

Please feel welcome to contact Us with any price or medical error. Our doctors will receive any reports.